Navigation Links
CEL-SCI Corporation Announces 2007 Financial Results

VIENNA, Va., Jan. 14 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) reports financial results for the fiscal year ending September 30, 2007.

CEL-SCI reports a net operating loss for fiscal year 2007 of $9,352,209 versus a net operating loss of $5,349,196 in fiscal year 2006. The loss per share for fiscal year 2007 was unchanged at $(0.10) compared to fiscal year 2006.

The cash from operating activities used during the year was about $4,890,100. CEL-SCI's assets during the year grew from $9.6 million in fiscal year 2006 to $20.7 million in fiscal year 2007.

Geert Kersten, Chief Executive Officer said, "CEL-SCI had a very successful year in that it received FDA go-ahead for a Phase III clinical trial with its cancer drug Multikine, raised substantial amounts of money and began building a dedicated manufacturing facility for Multikine. We are looking forward to taking over the completed facility in 2008 and starting the global Phase III trial."

About CEL-SCI's Phase III Cancer Drug Multikine:

In Phase II clinical trials Multikine was shown to be safe and well- tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.



YEARS ENDED SEPTEMBER 30, 2007 and 2006

2007 2006

GRANT REVENUE AND OTHER $ 57,043 $ 125,457


Research and development (excluding

R&D depreciation of $91,292, $74,043

and $96,442 respectively, included

below) 2,528,528 1,896,976

Depreciation and amortization 176,186 170,903

General & administrative 6,704,538 3,406,774

Total operating expenses 9,409,252 5,474,653

NET OPERATING LOSS (9,352,209) (5,349,196)




INTEREST INCOME 562,973 92,487

INTEREST EXPENSE (1,708,603) (216,737)

NET LOSS $ (9,629,657) $ (7,939,210)


BASIC $ (0.10) $ (0.10)

DILUTED $ (0.10) $ (0.11)



BASIC 97,310,488 78,971,290

DILUTED 97,310,488 93,834,078

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
3. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
8. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
9. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   Clinical ... --> Clinical Cancer Research vom ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... november 2015 AAIPharma Services Corp./Cambridge ... investering aan van ten minste $15,8 miljoen ... het mondiale hoofdkantoor in Wilmington, ... in extra kantoorruimte en extra capaciteit voor ... behoeften van de farmaceutische en biotechnologische markten. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... and Cambridge, ON (PRWEB) , ... November 26, ... ... the availability of a real-time eReferral system for diagnostic imaging in the Waterloo ... X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical record ...
Breaking Medicine News(10 mins):